Our sister molecular diagnostics company, FYR Diagnostics is a fast-growing Montana biotechnology company, based in Missoula. FYR is developing a powerful portfolio of biomarker detection technologies. FYR Diagnostics’ mission is to commercialize and implement these novel technologies to enable the accelerated diagnosis of human and agricultural diseases.
Novoron Bioscience is a private biotechnology company developing novel therapeutic approaches to address disorders of the central nervous system (CNS). Novorons’ mission is to develop therapeutics for the treatment of various disorders of the central nervous system (CNS), including multiple sclerosis (MS), spinal cord injury, glaucoma and Alzheimer’s disease.
In 2020, we partnered with MGH to develop a positron emission tomography (PET) imaging agent to objectively diagnose and measure pain. The project is supported by a grant from the National Institutes of Health’s Helping to End Addiction Long-term (NIH HEAL) Initiative.
MGH brings world-leading knowledge and expertise from researchers of varied backgrounds including chemistry, biochemistry, and medical physics. The chemical neuroscience program at the Martinos Center was formed in 2019 by a core group of Harvard faculty members at MGH that had collaborated through various career stages. The formation of the program solidified the organic collaborations into a model system for co-mentorship of future neuroscience imaging leaders and commitment to rigorous and impactful science.